5 Stocks to Sell Now According to Orkun Kilic’s Berry Street Capital

4. Omnicell, Inc. (NASDAQ:OMCL)

Berry Street Capital’s Stake Value In Q1 2022: $8 million

Percentage of Berry Street Capital’s 13F Portfolio In Q1 2022: 0.91%

Number of Hedge Fund Holders: 19

Omnicell, Inc. (NASDAQ:OMCL) is an American company that provides medication management and adherence tools for pharmacies and other healthcare companies. These allow for pharmacy automation, automated dispensing of medications, and other uses. The company is headquartered in Mountain View, California.

Berry Street Capital held an $8 million stake in Omnicell, Inc. (NASDAQ:OMCL) during Q1 2022, which came in the form of 62,500 shares. At the time, it represented 0.91% of the firm’s investment portfolio, but the firm sold all these shares as the second quarter ended. Insider Monkey’s Q2 2022 research covering 895 hedge funds saw 19 investors in the company.

Omnicell, Inc. (NASDAQ:OMCL)’s shares have dropped by 32% over the past six months – a factor that was undoubtedly on Mr. Kilic’s mind as his fund sold its entire stake in the company. Piper Sandler reduced the firm’s share price target to $150 from $162 in August 2022, stating that its second quarter results were impressive.

Omnicell, Inc. (NASDAQ:OMCL)’s largest investor in our database is Ken Fisher’s Fisher Asset Management which owns 256,333 shares that are worth $29 million.

Carillon Tower Advisers mentioned the company in its Q1 2022 investor letter. Here is what the fund said:

“Omnicell (NASDAQ:OMCL) provides an integrated suite of clinical infrastructure and workflow automation solutions for healthcare facilities. Cloud services have been a focus of the company and have shown good growth, automating many manual processes.”